Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Merck & Co Puts A Date On Spinning Off Biosimilars

Plans Have Been Public For 12 Months

Executive Summary

Merck & Co has disclosed more precise details around plans to spin off its more mature products, including biosimilars, into a new publicly traded company.

You may also be interested in...



Deal Watch: BMS Looks To Molecular Templates’ Engineered Toxin Bodies In Cancer

Plus recent deals involving AbbVie/Caribou, Sanofi/i2O, Merck & Co./Starpharma, Protalix/SarcoMed, Targovax/Papyrus, Medivir/Ubiquigent, Eton/Azurity

Samsung Bioepis Clears Up Second EU Bevacizumab Application

Samsung Bioepis last week received a second positive opinion recommending granting a pan-European marketing authorization for a biosimilar bevacizumab product. The Korean firm spoke to Generics Bulletin detailing the rationale.

FDA Approves Mylan’s Humira Biosimilar

Mylan’s Hulio has become the sixth biosimilar version of Humira to be approved by the US FDA. However, all of these adalimumab biosimilars face a wait until 2023 before they can enter the market.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

GB150644

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel